X4 Pharmaceuticals, Inc.
XFOR
$3.57
$0.071.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 225.18% | 5.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 225.18% | 5.45% | |||
| Cost of Revenue | 170.40% | 64.29% | |||
| Gross Profit | 240.71% | -4.26% | |||
| SG&A Expenses | 22.69% | -6.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.66% | -13.19% | |||
| Operating Income | 19.13% | 15.19% | |||
| Income Before Tax | 20.19% | 15.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.18% | 15.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.18% | 15.40% | |||
| EBIT | 19.13% | 15.19% | |||
| EBITDA | 23.21% | 15.33% | |||
| EPS Basic | 20.21% | 62.82% | |||
| Normalized Basic EPS | 20.10% | 63.19% | |||
| EPS Diluted | 18.90% | 62.88% | |||
| Normalized Diluted EPS | 20.10% | 63.19% | |||
| Average Basic Shares Outstanding | 0.04% | 13.32% | |||
| Average Diluted Shares Outstanding | 0.04% | 13.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||